Conclusions
NSCLC, lung cancer, tumours, PD‐L1
TUMOURS, NSCLC, LUNG CANCER
In conclusion, concurrent atezolizumab and SBRT were safely administered in metastatic NSCLC patients, yielding encouraging results in a subset of patients, including those with PD‐L1 negative tumours. Additional trials are needed to evaluate the optimal radiation dose, fractionation and sequence to increase systemic response rates. ctDNA holds potential as a dynamic biomarker in lung cancer patients receiving immunotherapy, however, questions remain concerning the robustness and practical implementation.